PATENTS
1) Treatment of Wounds
Application number: 20050148585
Abstract: This invention relates to the use of cyclic guanosine 3?, 5?-monophosphate type five (cGMP PDE5) inhibitors (hereinafter PDE5 inhibitors), including in particular the compound sildenafil, for the treatment of chronic wounds of a non-diabetic origin including in particular chronic venous ulcers, chronic decubitus (pressure sores) and arterial ulcers; and acute wounds.
Type: Application
Filed: August 26, 2004
Issued: July 7, 2005
Inventors: Michael Davies, Jonathan Huggins, Dinah Parums
2) 12 Amino Acid Sequence
Application number: 20050106638
Abstract: The present invention relates to an isolated target sequence. The target sequence is a splice variant of PDE5 called a PDE5a1, a component of which is presented as SEQ ID No 1. The identified target sequence of the present invention may be used to as a target to identify agents (such as modulators) useful in the prevention and/or treatment of a disease associated with scarring and/or fibrosis or to selectively identify smooth muscle cells and myofibroblasts and myoepithelial cells in samples of normal and diseased tissue from individuals.
Type: Application
Filed: August 30, 2004
Issued: May 19, 2005
Assignee: Pfizer Inc.
Inventors: Dinah Parums, Stephen Phillips, John Ridden
3) Target
Patent number: 6794192
Abstract: The present invention relates to an isolated target sequence. The target sequence is a splice variant of PDE5 called a PDE5a1, a component of which is presented as SEQ ID No 1. The identified target sequence of the present invention may be used to as a target to identify agents (such as modulators) useful in the prevention and/or treatment of a disease associated with scarring and/or fibrosis or to selectively identify smooth muscle cells and myofibroblasts and myoepithelial cells in samples of normal and diseased tissue from individuals.
Type: Grant
Filed: June 28, 2001
Issued: September 21, 2004
Assignee: Pfizer Inc.
Inventors: Dinah Parums, Stephen Charles Phillips, John Ridden
4) Target
Application number: 20030040041
Abstract: The present invention relates to an isolated target sequence. The target sequence is a splice variant of PDE5 called a PDE5a1, a component of which is presented as SEQ ID No 1. The identified target sequence of the present invention may be used to as a target to identify agents (such as modulators) useful in the prevention and/or treatment of a disease associated with scarring and/or fibrosis or to selectively identify smooth muscle cells and myofibroblasts and myoepithelial cells in samples of normal and diseased tissue from individuals.
Type: Application
Filed: June 28, 2001
Issued: February 27, 2003
Inventors: Dinah Parums, Stephen Charles Phillips, John Ridden
5) Treatment of wounds
Application number: 20020065286
Abstract: This invention relates to the use of cyclic guanosine 3′, 5′-monophosphate type five (cGMP PDE5) inhibitors (hereinafter PDE5 inhibitors), including in particular the compound sildenafil, for the treatment of chronic wounds of a non-diabetic origin including in particular chronic venous ulcers, chronic decubitus (pressure sores) and arterial ulcers; and acute wounds.
Type: Application
Filed: August 10, 2001
Issued: May 30, 2002
Inventors: Michael John Davies, Jonathan Paul Huggins, Dinah Parums
